BiondVax Pharmaceuticals, a publicly-traded company (TASE: BNDX) located in the Weizmann Science Park in Rechovot (Israel), is dedicated to the development of a novel Universal Influenza Vaccine. BiondVax's Universal Flu Vaccine is based on research carried out over a period of 20 years by Weizmann Institute Professor Ruth Arnon, who heads the company's Scientific Advisory Board. Professor Arnon is well-known for her part in the development of Copaxone®, a blockbuster drug for the treatment of multiple sclerosis.
The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing this innovative flu vaccine.
BiondVax’s team of 13 includes scientists, technicians, researchers, and administrative staff. The company’s state-of-the-art GMP facility in Rechovot houses its laboratories, production facilities and offices.
To date, BiondVax has raised a total of over US$15.5 million. Of this amount, approximately $4.1 million was raised from private investors and $2.0 million from the Israeli Office of the Chief Scientist. In June 2007, BiondVax started trading on the Tel-Aviv Stock Exchange (TASE: BNDX), raising an additional ~$3 million. In December 2009, BiondVax executed a follow-on offering on the Tel-Aviv Stock Exchange, raising an additional $5.3 million.
